Clin2
NCT07765823Possibly a fitRecruiting

N-acetylcysteine for liver failure not caused by acetaminophen

Acute Liver Failure

Treatments studied

Part of Digestive system clinical trials.

This trial tests whether the drug N-acetylcysteine (NAC) can help people with sudden liver failure that is not caused by acetaminophen (like Tylenol). If you qualify, you may receive NAC, which might help your liver recover.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
62 people
Ages
18 years to 60 years
Study type
Interventional

Who can take part

  • You must be between 18 and 60 years old.
  • You must have sudden liver failure that was NOT caused by taking too much acetaminophen (like Tylenol).
  • The cause of your liver failure should be from viral hepatitis (A, B, or E), a drug (other than acetaminophen), or an unknown cause.
  • You must NOT have already received N-acetylcysteine (NAC) for this episode of liver failure.
  • You cannot have a history of chronic liver disease or cirrhosis, or have had a liver transplant.
  • You cannot be pregnant, and you must not have severe heart, kidney, brain, or infectious diseases, or be allergic to NAC.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07556055Not yet recruiting
Causes and outlook for acute liver failure

This study looks at why acute liver failure happens and what factors affect recovery. It may help you and your doctor understand the condition better and guide treatment decisions.

NCT05557448Recruiting· Phase 2
N-Acetylcysteine treatment for serious acetaminophen overdose

This Phase 2 trial studies whether TYNADOTE® can treat people who have taken a harmful acetaminophen (Tylenol) overdose while checking safety. It may be considered if your overdose is high enough to put you at risk for liver injury and you can follow the treatment and follow-up visits.

Taipei, Beitou District
NCT07273071Recruiting· Phase 4
N-acetylcysteine for severe infections

This trial tests if N-acetylcysteine, a medicine that helps the liver and fights inflammation, can improve outcomes for adults with a severe infection and liver stress.

Copenhagen
NCT07803952Not yet recruiting· Phase 1/Phase 2
N-acetylcysteine for belly infection in cirrhosis

This study tests whether adding N-acetylcysteine (an antioxidant supplement) to standard treatment helps fight an infection in the belly fluid of people with liver cirrhosis. It aims to improve recovery and reduce complications.

NCT06260566Not yet recruiting· Phase 1
NAC syrup for babies with bile duct disease

This study tests whether a medicine called NAC (an antioxidant that helps protect the liver) can be safely given to infants with biliary atresia by mouth. It aims to see if babies can tolerate it, which might eventually help their liver health.

NCT06916585Recruiting· Phase 2
Testing AS1501 for acute-on-chronic liver failure

This trial tests a new drug called AS1501 for people with acute-on-chronic liver failure (a sudden worsening of chronic liver disease). It aims to see if the drug can help improve liver function and reduce the need for a liver transplant. You may be eligible if you are in the early or middle stage of this condition and have a specific blood marker (high TRAIL level).

Shenzhen, Guangdong

Hear when a new Acute Liver Failure trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.